Chen Wan-Shan
SEC Form 4 insider trading activity
Chen Wan-Shan has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company, with disclosures dating back to 2026. 1 of those filings fall inside the rolling window. Most recent filing: Apr 13, 2026.
On the most recent filing, Chen Wan-Shan is listed as Director at BELITE BIO, INC. Inside the rolling window, Chen Wan-Shan reported no open-market purchases and 1 open-market sale totaling $198K in BLTE.
Companies traded
Other insiders at BLTE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$198K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Chen Wan-Shan made?
Chen Wan-Shan has filed 1 SEC Form 4 filing (1 transaction rows) across 1 company since 2026.
Which companies does Chen Wan-Shan trade?
Chen Wan-Shan has filed SEC Form 4 disclosures for 1 company, including BLTE.
When was Chen Wan-Shan's most recent SEC Form 4 filing?
Chen Wan-Shan's most recent SEC Form 4 filing on Tracefour is dated Apr 13, 2026.
What is Chen Wan-Shan's total buy and sell value in the current window?
Inside the rolling retention window, Chen Wan-Shan bought $0 and sold $198K based on SEC Form 4 filings.
What was Chen Wan-Shan's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,100 BLTE shares on 2026-04-09, worth $198K, per SEC Form 4 filings.